Now part of Donaldson Company
Univercells Technologies by Donaldson offers cutting-edge biomanufacturing solutions for cost-effective viral production across all scales. Our technology harnesses process intensification and chaining, delivering higher performance while reducing costs and footprint. We build upon years of expertise and capitalize on technology developed by Univercells and vetted by world leaders to deliver the next evolution of biomanufacturing technologies.
History timeline
Univercells creation
Experienced entrepreneurs Hugues Bultot and José Castillo established Univercells in 2013. They seek the development of technologies in order to have a direct and meaningful impact on the way biologics are manufactured worldwide.
$12M grant to develop a vaccine platform
Bill and Melinda Gates Foundation granted Univercells $12M to develop a biomanufacturing platform to deliver inactivated polio (sIPV) vaccine doses at affordable costs and with a reduced footprint. This development is the first application and proof of concept of the NevoLine™ biomanufacturing platform.
New Equipment Design Center
Univercells inaugurated the new Equipment Design & Production Center in Nivelles, Belgium. Today the facility fosters Univercells Technologies’ activities including the development and delivery of state-of-art high-performance, scalable bioproduction technologies for viral products.
Introducing the NevoLine™ sIPV platform
Two years after receiving the Bill & Melinda Gates Foundation grant of $12M, Univercells introduced the NevoLine platform proof of concept to deliver affordable inactivated polio vaccine (sIPV). This first application demonstrated how the chaining of unit operations could intensify processes for drastic footprint and cost reductions.
€50M to speed delivery of manufacturing technologies
Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, supports Univercells Technologies activities by financing $50M. The investment will be deployed on accelerating the industrialization and commercialization of the NevoLine™ biomanufacturing platform and the scale-X™ bioreactor portfolio.
Official launch of Univercells Technologies
With its own identity, Univercells Technologies will focus on the commercialization of the product portfolio – the scale-X™ bioreactor range and the NevoLine™ biomanufacturing platform. The company will also explore new technologies and solutions developments to deliver the next evolution of biomanufacturing.
Introduction of the NevoLine™ Upstream platform
The new generation NevoLine platform builds upon the successfull proof of concept for sIPV manufacture designed and developped by Univercells. The NevoLine Upstream platform redefines upstream processing by integrating virus production, concentration and clarification for streamlined, high-performance virus manufacturing in a 3 m² footprint equipment.
Mathias Garny appointed as CEO of Univercells Technologies
Already acting as General Manager, Mr. Garny has been responsible for overseeing the Company’s operations and leading the strategy development and implementation. Under his leadership, the Company introduced new products and expanded international operations.
Donaldson Company acquires Univercells Technologies
Donaldson Company, a leading worldwide provider of innovative filtration products and solutions, acquires Univercells Technologies, broadens Life Sciences reach to bring end-to-end solutions to market for advanced therapies.